9th CML-CAB

CML-CAB 2019 III

CMLCAB-Logo

9th CML-CAB: Basel, Switzerland, 20 November 2019

 

On 20 November 2019, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its 9th meeting to discuss issues of major concern to the CML community.

CML-CAB Members attending this 9th CML-CAB as patient experts:

  • ·Jan Geissler, Germany (chair, Western Europe & Israel)
  • ·Pat Garcia-Gonzalez (co-chair, region North America)
  • ·Giora Sharf, Israel (Western Europe & Israel)
  • ·Jana Pelouchova, Czech Republic (Eastern Europe)
  • ·Bahija Gouimi, Morocco (region Africa)
  • ·Rod Padua, Philippines (region Asia)
  • ·Felice Bombaci, Italy (region Western Europe & Israel)
  • ·Šarūnas Narbutas, Lithuania (region Eastern Europe)
  • ·Lisa Machado, Canada (region North America)
  • ·José Castro, Costa Rica (region Latin America)
  • ·Zack Pemberton-Whiteley, United Kingdom (region Western Europe & Israel)

 

Topics discussed during this 9th CML Community Advisory Board (CML-CAB) meeting with Novartis included goals, issues and expectations from the CML community’s perspective, a discussion on patient-centric cure for CML and Q&A sessions on access today and tomorrow and on CML patients’ inputs into R&D. Discussions focused mainly on how to collaborate best to tackle issues with access to treatment/monitoring and clinical trials in LMICs and how to move forward towards a patient-centric cure for CML with CML-CAB.

Non-confidential minutes are available to CML Advocates Network members below:

pdf 9th CMLCAB November 2019 Novartis Minutes Non-confidential (771 KB)

 


 
   
 

EU e-Privacy Directive